## FLASH Effects: Focus on *in-Vitro* Studies

Manuela Buonanno Assistant Professor of Radiation Oncology Columbia University Irving Medical Center



## **FLASH effect**

# Radiation delivered at high dose rates ensure similar tumor control as radiation delivered at "conventional" dose rates but with reduced normal tissue toxicity


A biological effect strictly characterized by physics parameters

	Conventional	FLASH
Dose rates	1-2 Gy/min (0.02-0.03 Gy/s)	> 100 Gy/s
Dose delivery time	min	μs to ms
Dose per fraction	~ 2 Gy	≥ 10 Gy

### For pulsed beams:

- Mean dose rate vs. instantaneous dose rate (dose rate in the pulse)
- Time to deliver the dose
- Frequency or time between two pulses


#### Conditions to obtain or miss the FLASH effect




Adapted from Vozenin MC 2021 RRS Herman D. Suit plenary lecture

## **Normal tissue sparing - Lung**


- C57BL/6J mice
- bilateral thorax exposure
- single fraction



Arrows -> patches of subpleural fibrosis
Asterisks -> intraparenchymal fibrosis



## Normal tissue FLASH sparing effects have been observed in different species and organs



## Are tumors spared as well?

## The response of >23 tumor types have been compared using FLASH- & CONV-RT

- Syngeneic or xenograft tumors implanted subcutaneously or orthotopically in immune-competent or immune-compromised mouse models.
- Spontaneous tumors in larger vertebrates (dog and cat).

#### **Exceptions**

Lewis lung carcinoma and LM8 osteosarcoma FLASH-RT was shown to be **slightly more effective** than CONV-RT in slowing the growth of tumors (B.W. Loo Jr. et al., unpublished data) and in preventing metastasis when delivered with carbon ions (Tinganelli et al. 2022).

**Not effective** in all human T cell acute lymphoblastic leukemias (T-ALL) grafted into immunocompromised mice as patient-derived xenografts (Chabi et al. 2021). Following bone marrow transplantation/reconstitution, mice were given 4 Gy TBI FLASH-RT or CONV-RT; one T-ALL was more responsive to CONV-RT.

## In humans

The first patient with skin metastases from melanoma had one 3.5-cm diameter tumor treated with 15 Gy electron FLASH delivered in 90 ms.

- Complete tumor response at 36 days
- No recurrence after 5 months

Day 0






Bourhis J, et al. Radiother Oncol. 2019;139:18-22

Varian and the Cincinnati Children's/UC Health Proton Therapy Center trial of patients enrolled in the FAST-01 or **FeA**sibility **S**tudy of FLASH Radiotherapy for the palliative **T**reatment of **symptomatic bone metastases** 

- 10 patients underwent FLASH radiotherapy (8Gy at 60 Gy/sec) at 12 metastatic sites.
- Transient pain flares occurred in 4 of the 12 treated sites (33%). In 8 of the 12 sites (67%) patients reported pain relief, and in 6 of the 12 sites (50%) patients reported a complete response (no pain).
- Phase 2 has started.

## Clinical advantages

- Increase of the therapeutic index
- Reduction of dose fractions
- Reduced treatment time, overall course, and costs




Chang, D.S et al, (2014). Therapeutic Ratio. In: Basic Radiotherapy Physics and Biology. Springer, Cham.

## **Ongoing challenges**


- Beam parametrization and standardization
- Type of radiation that can elicit FLASH effects
- Fractionation
- Dose rate effects on tumor volume
- Dose rate effects depending on the organ
- Late effects
- Unidentified molecular mechanisms

## **Mechanism(s) for the FLASH Sparing Effects**



Distinctive molecular mechanisms still unknown. How can FLASH-RT discriminate between normal and tumor tissue? Are the intrinsic determinants at cellular or tissue level?

## What are the mechanisms for the FLASH sparing effects?



The yields of different radical species and how they diffuse, react, recombine, and form new radical products during FLASH vs. CONV could influence the biological responses downstream.

## In vitro studies


In vivo investigation are essential, but a pinch of reductionism is still needed:

- Basic studies with the simplest conditions (normal cells and their cancer counterparts) are useful to investigate molecular mechanisms so that treatment protocols can be refined.
- Findings in normoxia can be used as benchmark.
- What is the major player in the redox metabolism is under debate.


## Still unknown

- Molecular mechanisms leading to the FLASH effect
- Precise experimental conditions (i.e. beam parameters, oxygen level in cells) required to elicit the effect
- What type of radiation does elicit the effect?









## At the Radiological Research Accelerator Facility (RARAF)

#### **Proton FLASH**

5 MeV protons, LET ~10 keV/µm Dose rate up to 1 kGy/sec (limited by pulse length)

Geometry:

< 1-cm diameter

< 300-µm thick





#### **Electron FLASH**

Cornell University donated a decommissioned Linac 6-9 MeV electrons
Dose rate ~200 Gy/sec
Will allow hemi-mouse irradiations:

4-cm field size >2-cm thick




### **Acute Effects**

**Clonogenic survival:** The dose rate of 4.5 MeV protons does not affect survival of normal and cancer cells under normoxic conditions.

**DNA damage**: The effects might be more evident at relatively higher doses.






### **Long-term effects: Radox metabolism**


Normal cells, 20 Gy protons, 0.05, 100, 1000 Gy/s

#### Senescent IMR90 one month after exposure



Cell senescence - a potential mechanistic link between radiation-induced oxidative stress and prolonged tissue injury


## TGFβ in normal human fibroblast 24 h and one month after exposure



Senescent cells release proinflammatory molecules; TGFβ1 is one of the major player in modulating such signals

#### Redox metabolism: Mitochondria

Normal cells, 15 Gy protons, 20 vs. 6000 Gy/min





- CM-H<sub>2</sub>DCFDA general ROS indicator
- N-Acetyl-L-cysteine (NAC) ROS inhibitor





#### Mitochondria structure

15 Gy protons, 20 vs. 6000 Gy/min - Mitotracker green












### Mitochondria dynamics – Drp1

- Mitochondrial maintain their shape, size, and distribution through coordinated cycles of fission and fusion.
- The fission protein dynamin-related protein 1
   (Drp1) is a GTPase that upon activation
   translocate from the cytoplasm to
   mitochondria.
- It stabilizes p53 and is required for p53 translocation to the mitochondria under oxidative stress.









Normal cells, 15 Gy protons 20 vs 6000 Gy/min

Expression of Drp1
Mitotracker red & Alexa488/anti-Drp1


Drp-1/p53 co-localization
Alexa488/anti-Drp1 & Alexa555/anti-p53

## Inhibition of Drp1 by Mdivi-1






## Inhibition of Drp1 by Mdivi-1




#### Mitochondria length



Expression of Drp1

Mitotracker red & Alexa488/anti-Drp1




### Mitochondria functions 1


Mitochondria membrane potential (JC-1)

J-aggregates in mitochondrial matrix -> red fluorescence


JC-1 monomers do not aggregate in the matrix and fluoresce green



(RT-PCR ratio mtDNA/nDNA or 12SrRNA/18SrRNA)



## Mitochondria functions 2



#### Mdivi-1, inhibitor of Drp1

#### Cellular ATP


Luciferase enzyme/luciferin luminescence

Extracellular oxygen consumption

Fluorescence ratio 380/650 nm


## **Pre-clinical studies**













## Redox metabolism: Expression of carbonic anhydrase IX in 3-D tissues



- Carbonic anhydrase IX is membrane-bound enzyme generally associated with hypoxia in many tumor cell lines.
- In normal tissues, it is involved in maintaining optimal pH for cell survival and it is directly linked to radiation-induced activation of TGFβ.

An increase in dose rate resulted in the reduction of CAIX expression 3 months after irradiation



## In cells exposed to protons <u>under ambient oxygen tension</u>, CONV, but not FLASH:

#### Inflammatory responses

Induced senescence

TGFb expression

ROS

CAIX expression 3 months after irradiation

#### Mitochondria

Damage to structure (shape, size, copy number)

Damage to functions (ATP release, MMP, oxygen consumption)

Increased Drp1 expression/translocation to mitochondria, but not the phosphorylated form

#### Cell death

Induced necrosis (as opposed to autophagy and apoptosis)

Compared to CONV-, proton FLASH-RT seems to preserve redox functions in normal cells

## **Probable Mechanism(s) for the Sparing Effects?**

#### Transient hypoxia?

#### **Tumors**

They may not be able to cope with the increase in FLASH-induced free radicals;

Due to more iron, Fenton-based reactions may sustain free radical chain reactions.

#### Healthy tissue

Limited cytokine activation including TGFβ and less inflammatory reaction.

#### **However:**

**No oxygen depletion** (Vozenin team showed it with Fricke solution and OxyLite monitor in aqueous solutions & Oxyphor 2P probe in vitro and in vivo). It requires very high doses (e.g., 100 Gy).

Difference in radiolysis yields TBD

#### Reduced DNA damage and senescent cells

Chromatin remodeling mediated by poly (ADP-ribose) polymerase

Stem cell protection

Reduction of fraction of circulating blood cell irradiated and sparing of the immune system (under debate)


**Proteins, lipids** 

Metabolism (low metabolic activity/hibernation)

**Mitochondria** 

. . .

## **Mechanism(s) for the FLASH Sparing Effects**




Distinctive molecular mechanisms still unknown Pre-clinical studies are needed to inform clinical approaches

## What's next in our lab

#### Grant application in collaboration with the Université de Sherbrooke, Canada

Mechanistic studies of the chemical and biological effects of ultra-high dose-rate proton radiation

- 1. Simulation & modeling: Jean-Paul Jay-Gerin
- 2. Chemical changes in DNA: Richard Wagner
- 3. Biological experiments: Manuela Buonanno, Guy Garty, & Ed Azzam



#### **Ongoing collaboration with Weil Cornell University**

Mechanistic studies of the chemical and biological effects of ultra-high dose-rate radiation using patient derived organoids

 Normal and breast tissue organoids derived from the same patient studied separately or as a single organoid containing both tissue types to better mimic the real tumor/normal tissue microenvironment.

## Thank you for your attention

#### Thanks to

- NCI 1UO1CA236554
- Pilot grant from the Department of Radiation Oncology Columbia University Irving Medical Center (CUIMC)
- Dr. Guy Garty and the physicists at RARAF
- Radiation Oncology departments at CUIMC and Weil Cornell Medicine

